Since NF-L is located in large caliber myelinated axons of neurons only, most clinical analyses were performed in the cerebrospinal fluid (CSF) of Multiple Sclerosis (MS) patients ( Kuhle et al., 2013b) but also tissue of other neurodegenerative diseases were already analyzed in detail. Furthermore, our data indicate that NF-L might also be a good biomarker for disorders with a neuronal component like some lysosomal storage diseases.ĭuring the last years, Neurofilament-light chain (NF-L) has been shown to be a valuable biomarker for several neurodegenerative diseases ( Gaetani et al., 2019). Compared to analyses in human tissues, our results suggest a high translation value of murine NF-L levels and their progression. NF-L measurements in the plasma of the neurodegenerative disease mouse models of ALS and AD are thus a good tool to evaluate disease progression. Most analyzed models show a progressive increase of NF-L levels. Our results show that NF-L levels are highly increased in the plasma of ALS, Alzheimer’s and GD models, while in the analyzed Parkinson’s disease model NF-L plasma levels barely changed. We therefore evaluated NF-L levels in the plasma of the ALS models SOD1-G93A low expressor and TAR6/6 mice, the Alzheimer’s disease (AD) model 5xFAD, the Parkinson’s disease model Line 61 and the Gaucher disease (GD) model 4L/PS-NA and the CSF of selected models. Detailed analyses of NF-L expression in neurodegenerative disease patient’s samples were already performed, while NF-L levels of preclinical models of ALS, Alzheimer’s and Parkinson’s disease as well as lysosomal storage diseases are still widely unknown. The use of plasma for NF-L measurement makes this biomarker exceptionally valuable for clinical studies since sample collection can be performed repeatedly without causing much harm. By analyzing amyotrophic lateral sclerosis (ALS) patients cerebrospinal fluid (CSF) or plasma, progression of NF-L levels can forecast conversion from the presymptomatic to symptomatic stage and time of survival. Neurofilament-light chain (NF-L) is a well-known clinical biomarker of many neurodegenerative diseases.
0 Comments
Leave a Reply. |